DBV Technologies (NASDAQ:DBVT) Announces Quarterly Earnings Results, Misses Expectations By $0.55 EPS

Key Points

• DBV Technologies reported a quarterly loss of $0.70 per share, missing analyst expectations by $0.55. Revenue was $1.60 million, exceeding the $0.73 million consensus estimate.
• The company remains deeply unprofitable, with a negative net margin of 3,506.53% and negative return on equity of 119.33%, while its lead candidate is the investigational Viaskin Peanut patch for peanut allergies.
• Shares rose 5.4% to $10.68 after the earnings release. Analyst sentiment remains mostly positive, with a “Moderate Buy” consensus and a $48.50 average price target, despite one recent downgrade to “sell.”

DBV Technologies (NASDAQ:DBVT - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.55), FiscalAI reports. DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 119.33%. The company had revenue of $1.60 million for the quarter, compared to analysts' expectations of $0.73 million.

DBV Technologies Trading Up 5.4%

DBVT traded up $0.55 during trading on Wednesday, hitting $10.68. 225,613 shares of the company's stock were exchanged, compared to its average volume of 316,799. DBV Technologies has a 1 year low of $8.63 and a 1 year high of $26.18. The stock has a 50 day moving average price of $11.79 and a 200 day moving average price of $17.04. The firm has a market cap of $671.56 million, a P/E ratio of -3.04 and a beta of -1.04.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Wall Street Zen downgraded DBV Technologies from a "hold" rating to a "sell" rating in a research note on Saturday, July 4th. HC Wainwright restated a "buy" rating on shares of DBV Technologies in a report on Tuesday, June 30th. Cantor Fitzgerald restated an "overweight" rating on shares of DBV Technologies in a research note on Thursday, September 10th. Citigroup restated a "market outperform" rating on shares of DBV Technologies in a research note on Wednesday, September 30th. Finally, Citizens Jmp raised their price objective on DBV Technologies from $47.00 to $55.00 and gave the stock a "market outperform" rating in a report on Tuesday, June 30th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, DBV Technologies presently has an average rating of "Moderate Buy" and a consensus price target of $48.50.

About DBV Technologies

DBV Technologies SA NASDAQ: DBVT is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company's approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies' lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.